Bio Medica Laboratories
Live Updates, GMP, Subscription Data, and Financial Details
IPO Overview
Listed
Dates
May 21 to May 25 2026
Price Band
₹132 - 139
Current GMP
₹111.2 (-20.00%)
Subscription
2.26 times
IPO Details
| IPO Date | 21 to 25 May, 2026 |
| Listing Date | Fri, May 29, 2026 |
| Face Value | ₹ 10 per share |
| Price Band | ₹132 to ₹139 |
| Issue Price | ₹139 per share |
| Lot Size | 1,000 Shares |
| Sale Type | Fresh capital cum OFS |
| Issue Type | Bookbuilding IPO |
| Listing At | NSE SME |
| Total Issue Size | 37,72,000 shares (agg. up to ₹ 52 Cr) |
| Reserved for Market Maker | 1,89,000 shares (agg. up to ₹ 3 Cr) Prabhat Financial Services Ltd. |
| Fresh Issue (Ex Market Maker) | 32,06,000 shares (agg. up to ₹ 45 Cr) |
| Offer for Sale | 3,77,000 shares of ₹ 10 (agg. up to ₹ 5 Cr) |
| Net Offered to Public | 35,83,000 shares (agg. up to ₹ 50 Cr) |
| Share Holding Pre Issue | 91,80,001 shares |
| Share Holding Post Issue | 1,25,75,001 shares |
| / NSE Symbol | / BMLL |
| ISIN | INE1BKA01015 |
IPO Date
21 to 25 May, 2026
Listing Date
Fri, May 29, 2026
Face Value
₹ 10 per share
Price Band
₹132 to ₹139
Issue Price
₹139 per share
Lot Size
1,000 Shares
Sale Type
Fresh capital cum OFS
Issue Type
Bookbuilding IPO
Listing At
NSE SME
Total Issue Size
37,72,000 shares (agg. up to ₹ 52 Cr)
Reserved for Market Maker
1,89,000 shares (agg. up to ₹ 3 Cr) Prabhat Financial Services Ltd.
Fresh Issue (Ex Market Maker)
32,06,000 shares (agg. up to ₹ 45 Cr)
Offer for Sale
3,77,000 shares of ₹ 10 (agg. up to ₹ 5 Cr)
Net Offered to Public
35,83,000 shares (agg. up to ₹ 50 Cr)
Share Holding Pre Issue
91,80,001 shares
Share Holding Post Issue
1,25,75,001 shares
/ NSE Symbol
/ BMLL
ISIN
INE1BKA01015
IPO Subscription Details
| Market Maker | 1 |
| QIB (Ex Anchor) | 15.94 |
| NII*** | 1.30 |
| bNII (> ₹10L) | 0.86 |
| sNII (< ₹10L) | 2.19 |
| Individual Investors | 2.92 |
| Total ** | 2.26 |
Market Maker
1
QIB (Ex Anchor)
15.94
NII***
1.30
bNII (> ₹10L)
0.86
sNII (< ₹10L)
2.19
Individual Investors
2.92
Total **
2.26
Day Wise Sub
| Day | QIB (Ex Anchor) | NII* | NII (> ₹10L) | NII (< ₹10L) | Individual Investors | Total |
|---|---|---|---|---|---|---|
| May 2 1 (Day 1) | 15.94 | 0.03 | 0.01 | 0.06 | 1.09 | 0.72 |
| May 2 2 (Day 2) | 15.94 | 0.28 | 0.19 | 0.46 | 1.42 | 1.01 |
| May 2 5 (Day 3) | 15.94 | 1.30 | 0.86 | 2.19 | 2.92 | 2.26 |
DayMay 2
1 (Day 1)
QIB (Ex Anchor)15.94
NII*0.03
NII (> ₹10L)0.01
NII (< ₹10L)0.06
Individual Investors1.09
Total0.72
DayMay 2
2 (Day 2)
QIB (Ex Anchor)15.94
NII*0.28
NII (> ₹10L)0.19
NII (< ₹10L)0.46
Individual Investors1.42
Total1.01
DayMay 2
5 (Day 3)
QIB (Ex Anchor)15.94
NII*1.30
NII (> ₹10L)0.86
NII (< ₹10L)2.19
Individual Investors2.92
Total2.26
Day Wise GMP
| Date | Price | GMP | Estimate List Price |
|---|---|---|---|
| 29-05-2026 | 139.00 | -9(-6.47%) | 130 |
| 28-05-2026 | 139.00 | -9(-6.47%) | 130 |
| 27-05-2026 | 139.00 | -6(-4.32%) | 133 |
| 26-05-2026 | 139.00 | -6(-4.32%) | 133 |
| 25-05-2026 | 139.00 | 0(0.00%) | 139 |
| 24-05-2026 | 139.00 | 0(0.00%) | 139 |
| 23-05-2026 | 139.00 | 0(0.00%) | 139 |
| 22-05-2026 | 139.00 | 0(0.00%) | 139 |
| 21-05-2026 | 139.00 | 3.5(2.52%) | 142.5 |
| 20-05-2026 | 139.00 | 0(0.00%) | 139 |
| 19-05-2026 | 139.00 | 0(0.00%) | 139 |
| 18-05-2026 | 139.00 | 0(0.00%) | 139 |
| 17-05-2026 | 0(%) | (%) |
Date29-05-2026
Price139.00
GMP-9(-6.47%)
Estimate List Price130
Date28-05-2026
Price139.00
GMP-9(-6.47%)
Estimate List Price130
Date27-05-2026
Price139.00
GMP-6(-4.32%)
Estimate List Price133
Date26-05-2026
Price139.00
GMP-6(-4.32%)
Estimate List Price133
Date25-05-2026
Price139.00
GMP0(0.00%)
Estimate List Price139
Date24-05-2026
Price139.00
GMP0(0.00%)
Estimate List Price139
Date23-05-2026
Price139.00
GMP0(0.00%)
Estimate List Price139
Date22-05-2026
Price139.00
GMP0(0.00%)
Estimate List Price139
Date21-05-2026
Price139.00
GMP3.5(2.52%)
Estimate List Price142.5
Date20-05-2026
Price139.00
GMP0(0.00%)
Estimate List Price139
Date19-05-2026
Price139.00
GMP0(0.00%)
Estimate List Price139
Date18-05-2026
Price139.00
GMP0(0.00%)
Estimate List Price139
Date17-05-2026
Price
GMP0(%)
Estimate List Price(%)
IPO Important Dates
| IPO Open | Thu, May 21, 2026 |
| IPO Close | Mon, May 25, 2026 |
| Allotment | Tue, May 26, 2026 |
| Refund | Wed, May 27, 2026 |
| Credit of Shares | Wed, May 27, 2026 |
| Listing | Fri, May 29, 2026 |
IPO Open
Thu, May 21, 2026
IPO Close
Mon, May 25, 2026
Allotment
Tue, May 26, 2026
Refund
Wed, May 27, 2026
Credit of Shares
Wed, May 27, 2026
Listing
Fri, May 29, 2026
IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Individual investors (Retail) (Min) | 2 | 2,000 | ₹2,78,000 |
| Individual investors (Retail) (Max) | 2 | 2,000 | ₹2,78,000 |
| S-HNI (Min) | 3 | 3,000 | ₹4,17,000 |
| S-HNI (Max) | 7 | 7,000 | ₹9,73,000 |
| B-HNI (Min) | 8 | 8,000 | ₹11,12,000 |
ApplicationIndividual investors (Retail) (Min)
Lots2
Shares2,000
Amount₹2,78,000
ApplicationIndividual investors (Retail) (Max)
Lots2
Shares2,000
Amount₹2,78,000
ApplicationS-HNI (Min)
Lots3
Shares3,000
Amount₹4,17,000
ApplicationS-HNI (Max)
Lots7
Shares7,000
Amount₹9,73,000
ApplicationB-HNI (Min)
Lots8
Shares8,000
Amount₹11,12,000
Financial Information
| Period Ended | 30 Nov 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 65.17 | 39.12 | 19.53 | 17.57 |
| Total Income | 28.63 | 38.33 | 15.34 | 16.25 |
| Profit After Tax | 8.66 | 9.79 | 2.50 | 0.33 |
| EBITDA | 13.45 | 15.21 | 5.63 | 1.70 |
| NET Worth | 17.12 | 14.73 | 4.94 | 2.44 |
| Reserves and Surplus | 7.94 | 5.55 | 4.84 | 2.34 |
| Total Borrowing | 38.17 | 15.01 | 10.49 | 9.61 |
Period EndedAssets
30 Nov 202565.17
31 Mar 202539.12
31 Mar 202419.53
31 Mar 202317.57
Period EndedTotal Income
30 Nov 202528.63
31 Mar 202538.33
31 Mar 202415.34
31 Mar 202316.25
Period EndedProfit After Tax
30 Nov 20258.66
31 Mar 20259.79
31 Mar 20242.50
31 Mar 20230.33
Period EndedEBITDA
30 Nov 202513.45
31 Mar 202515.21
31 Mar 20245.63
31 Mar 20231.70
Period EndedNET Worth
30 Nov 202517.12
31 Mar 202514.73
31 Mar 20244.94
31 Mar 20232.44
Period EndedReserves and Surplus
30 Nov 20257.94
31 Mar 20255.55
31 Mar 20244.84
31 Mar 20232.34
Period EndedTotal Borrowing
30 Nov 202538.17
31 Mar 202515.01
31 Mar 202410.49
31 Mar 20239.61
Key Performance Indicator
| ROE | 54.41% |
| ROCE | 23.22% |
| Debt/Equity | 2.23 |
| RoNW | 54.41% |
| PAT Margin | 30.35% |
| EBITDA Margin | 47.11% |
| Price to Book Value |
ROE
54.41%
ROCE
23.22%
Debt/Equity
2.23
RoNW
54.41%
PAT Margin
30.35%
EBITDA Margin
47.11%
Price to Book Value
IPO Reservation
| QIB Shares Offered | 36,000 |
| NII (HNI) Shares Offered | 17,55,000 |
| − bNII > ₹10L | 11,70,000 |
| − sNII < ₹10L | 5,85,000 |
| Retail Shares Offered | 17,92,000 |
| Market Maker Shares Offered | 1,89,000 |
| Total Shares Offered | 37,72,000 |
QIB Shares Offered
36,000
NII (HNI) Shares Offered
17,55,000
− bNII > ₹10L
11,70,000
− sNII < ₹10L
5,85,000
Retail Shares Offered
17,92,000
Market Maker Shares Offered
1,89,000
Total Shares Offered
37,72,000
Information about company
Incorporated in August 2015, Bio Medica Laboratories specialises in manufacturing pharmaceutical parenteral formulations, producing a wide range of ethical drugs, generic drugs, and over-the-counter (OTC) medications in liquid and dry-powder injectable forms.der injectables. These injectables are available in both single-dose and multi-dose formats, serving the needs of both human and veterinary healthcare.
Product portfolio:
It offers comprehensive range of products, including generic drugs, branded pharmaceuticals, over the counter (OTC) products, and other medications.
The company operates on a B2B model, focusing exclusively on contract manufacturing. It develop formulations for various companies in accordance with their specific requirements and product specifications. It is certified for Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP) certificate issued by the Food & Drugs Administration, Madhya Pradesh.
It has two manufacturing facilities in Indore, Madhya Pradesh.
Competitive Strengths
Objectives of IPO
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
#: Issue Objects
1: Repayment of loan
2: Enhancement of its existing production capabilities by setting up of new manufacturing facility at the existing premises
3: General Corporate Purposes
4: Offer for Sale (OFS)
5: Issue Expense
: Total
Disclaimer
All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions.
We are not a SEBI Registered analyst. Readers must consult a qualified financial advisor prior to making any actual investment decisions, based on Information published on this application.
No financial information whatsoever published anywhere, within this application, should be considered as advice to buy or sell securities or invest in IPOs, or as a guide to doing so in any way whatsoever
Please read all Tearms and conditions , and agree to use the App